Oct 9, 2025
ADCE-D01 is a first-in-class antibody-drug conjugate targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes Fast Track designation underscores the potential for ADCE-D01 to address the...
Aug 27, 2025
COPENHAGEN, Denmark, Aug. 27, 2025 – Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor...
Jun 10, 2025
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe Copenhagen,...
Apr 23, 2025
ADCE-T02 – a potential first and best-in-class topoisomerase-1 (Topo-1) inhibitor-based Antibody-Drug Conjugate (ADC) against Tissue Factor – demonstrates strong and broad preclinical efficacy and good tolerability ADCE-D01 – a first-in-class ADC...
Apr 1, 2025
Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran RoyBaynes M.D., Ph.D. appointed as independent, non-executive Director Fang Z. Ni, Pharm.D. named Chief Financial Officer Company expands global footprint by establishing U.S....
Feb 26, 2025
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors Phase I Tiffany-01 trial is designed to evaluate the safety, pharmacokinetics,...